Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS

Learn more about:
Related Clinical Trial
Safety & Efficacy Study of Epcoritamab in Subjects With R/R Chronic Lymphocytic Leukemia and Richter’s Syndrome ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma R-EPOCH in Combination With Ibrutinib for Patients With Classical RT of CLL Phase 1 Study VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome A Study to Evaluate the Efficacy and Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Patients With Richter’s Syndrome; Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory NHL, RT, MM, T-PLL, Acute Leukemia (AML, ALL), MDS, MDS/MPN, and MF Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter’s Transformation Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma Venetoclax in Combination With Ublituximab and Umbralisib (TGR-1202) in Patients With Relapsed or Refractory CLL/SLL Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia Allogeneic Stem Cell Transplant for CLL Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin’s Lymphomas Atezolizumab, Gemcitabine, Oxaliplatin, and Rituximab in Treating Patients With Relapsed or Refractory Transformed Diffuse Large B-Cell Lymphoma Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter’s Transformation Registry of the German CLL Study Group Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies Study of Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone (CHOP) With Ofatumumab in Patients With Richter’s Syndrome PNT2258 for Treatment of Patients With Richter’s Transformation (Brighton) Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter’s Transformation Efficacy and Safety of Zanubrutinib Plus Tislelizumab for Treatment of Patients With Richter Transformation BLINAtumomab After R-CHOP Debulking Therapy for Patients With Richter Transformation Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter’s Transformation and Leukemias Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter`s Transformation Requiring Allogeneic Stem Cell Transplantation Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170) Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS Study of Blinatumomab in Richter Transformation Genomic and Proteomic Study of Richter Syndrome (CGPSR) CRC043: A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R for Patients With Richter’s Syndrome Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter’s Transformation or Richter’s Syndrome Patients Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter’s Syndrome A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter’s Syndrome Selinexor in Initial or Refractory and/or Relapsed Richter’s Transformation

Brief Title

Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS

Official Title

A Phase I/II Study of Duvelisib and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma or Patients With Richter's Syndrome

Brief Summary

      This research study is assessing a new drug, duvelisib, in combination with a drug that is
      already FDA approved, venetoclax, as a possible treatment for participants with CLL or those
      with Richter's Syndrome
    

Detailed Description

      This is a Phase I/II clinical trial. A Phase I clinical trial tests the safety of an
      investigational drugs and also tries to define the appropriate dose of the investigational
      drugs to use for further studies. "Investigational" means that the drugs are being studied
      together for the first time.

      This phase I study tests the safety of the drug duvelisib when used in combination with the
      drug venetoclax. Duvelisib is still being studied, but the FDA (the U.S. Food and Drug
      Administration) has approved the use of Duvelisib in patients with CLL/SLL with relapsed or
      refractory CLL after having received 2 or more prior therapies.

      Duvelisib is a drug that is given in capsule form and taken by mouth. This drug is designed
      to stop cancer growth by blocking a protein called phosphatidylinositide 3-kinase (PI3K),
      which is important for the survival of CLL cells. In laboratory studies and in other clinical
      trials that included participants with CLL, duvelisib was effective at killing CLL cells.

      Venetoclax is a tablet that is taken by mouth. Venetoclax targets a protein called BCL-2,
      which helps cancer cells survive. Venetoclax is an effective treatment for many participants
      with CLL who do not respond to chemotherapy or other approved drugs or who have relapsed
      after prior therapy.Venetoclax is FDA approved for participants with CLL who have never had
      therapy before or whose CLL has worsened after prior therapy.

      In the phase I portion of this study, the investigators are looking to determine the dose of
      venetoclax that is safe to give with duvelisib and to see what the side effects are of this
      combination.

      In the phase II portion of this study, we are looking to determine how effective
      thecombination of duvelisib and venetoclax is for patients with CLL or Richter's Syndrome
    

Study Phase

Phase 1/Phase 2

Study Type

Interventional


Primary Outcome

Maximum Tolerated Dose of Venetoclax When Administered with Duvelisib

Secondary Outcome

 Cmax

Condition

Chronic Lymphocytic Leukemia

Intervention

Duvelisib

Study Arms / Comparison Groups

 Duvelisib +Venetoclax,
Description:  Duvelisib will be given alone for the first seven days. On day 8 Venetoclax will be added.
Duvelisib will be administered orally twice daily
Venetoclax will be administered orally daily
All patients will be admitted for administration of the initial dose of venetoclax at each dose escalation

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

67

Start Date

July 12, 2018

Completion Date

June 1, 2024

Primary Completion Date

June 1, 2022

Eligibility Criteria

        Inclusion Criteria:

          -  Must have a confirmed diagnosis of chronic lymphocytic leukemia or small lymphocytic
             lymphoma requiring therapy, as per IW-CLL 2008 criteria OR Biopsy proven
             transformation to diffuse large B cell lymphoma (DLBCL), consistent with Richter's
             Syndrome

          -  Disease that has progressed during or relapsed after at least one previous CLL/SLL
             therapy - If Richter's Syndrome, this criterion is not applicable

          -  Age greater to or equal to 18 years

          -  ECOG performance status ≤2 (Karnofsky ≥60%)

          -  Patients must meet the following hematologic criteria at screening, unless they have
             significant bone marrow involvement of CLL confirmed on biopsy:

               -  Absolute neutrophil count ≥500 cells/mm3 (0.5 x 109/L). Growth factor is allowed
                  in order to achieve this

               -  Platelet count ≥25,000 cells/mm3 (25 x 109/L) independent of transfusion within 7
                  days of screening

          -  Adequate hepatic function defined as:

             --Serum aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3.0 x upper
             limit of normal (ULN), bilirubin ≤1.5 x ULN (unless bilirubin rise is due to Gilbert's
             syndrome or of non-hepatic origin

          -  Adequate renal function as defined as:

             --Serum creatinine ≤1.5 times the upper limit of normal or creatinine clearance ≥ 50
             mL/min using a 24-hour urine collection

          -  Women of child-bearing potential and men must agree to use adequate contraception
             (hormonal, barrier method or abstinence) prior to study entry and for the duration of
             study participation

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Previous treatment with venetoclax or duvelisib

          -  Patients receiving cancer therapy (i.e., chemotherapy, radiation therapy,
             immunotherapy, biologic therapy, surgery within 2 weeks of Cycle 1/Day 1 with the
             following exceptions:

               -  For patients on targeted therapies, a washout of least five half lives is
                  required

               -  Patients who experience clinical deterioration may start therapy after a shorter
                  washout period with prior approval by the PI

               -  Corticosteroid therapy (prednisone or equivalent <20 mg daily) is allowed

          -  Confirmed central nervous system involvement

          -  Allogeneic hematologic stem cell transplant within 6 months of starting study
             treatment or active graft vs. host disease (GVHD) requiring treatment or prophylaxis

          -  History of active malignancy requiring therapy with the exception of hormonal therapy

          -  Any active systemic infection requiring IV antibiotics or uncontrolled, active
             infections

          -  Known history of human immunodeficiency virus (HIV), hepatitis C virus (HCV), or
             hepatitis B virus (HBV)

          -  Major surgery within 4 weeks of first dose of study drug

          -  Currently active gastrointestinal disease, including colitis, inflammatory bowel
             disease and diarrhea requiring therapy

          -  Currently active, clinically significant cardiovascular disease, such as uncontrolled
             arrhythmia or Class 3 or 4 congestive heart failure as defined by the New York Heart
             Association Functional Classification; or a history of myocardial infarction, unstable
             angina, or acute coronary syndrome within 6 months prior to randomization

          -  Any life-threatening illness, medical condition, or organ system dysfunction that, in
             the investigator's opinion, could compromise the subject's safety or put the study
             outcomes at undue risk

          -  Use of Coumadin for anticoagulation (other anticoagulants permitted)

          -  Lactating or pregnant

          -  Concurrent administration of medications or foods that are strong inhibitors or
             inducers of CYP3A (see Appendix D) . The concomitant use of drugs or foods that are
             strong or moderate inhibitors or inducers of CYP3A are not allowed beginning 1 week
             prior to the first dose of duvelisib.

          -  Patients with ongoing use of prophylactic antibiotics are eligible as long as there is
             no evidence of active infection and the antibiotic is not included on the list of
             prohibited medications

          -  Unable to swallow capsules or malabsorption syndrome, disease significantly affecting
             gastrointestinal function, or resection of the stomach or small bowel, symptomatic
             inflammatory bowel disease or ulcerative colitis, or partial or complete bowel
             obstruction resulting in malabsorption or chronic diarrhea

          -  Active abuse of alcohol

          -  History of chronic liver disease or veno-occlusive disease/sinusoidal obstruction
             syndrome

          -  History or concurrent condition of interstitial lung disease of any severity and/or
             severely impaired lung function

          -  Known hypersensitivity to duvelisib and/or its excipients

          -  History of tuberculosis treatment within the 2 years prior to initiation of therapy
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Matthew S Davids, MD, 617-632-3539, [email protected]

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT03534323

Organization ID

18-089


Responsible Party

Principal Investigator

Study Sponsor

Dana-Farber Cancer Institute

Collaborators

 Secura Bio, Inc.

Study Sponsor

Matthew S Davids, MD, Principal Investigator, Dana-Farber Cancer Institute


Verification Date

November 2021